Sione Crawford
Biographic Data
| ID | 5557945 |
|---|---|
| NAME | Sione Crawford |
| GIVEN NAMES | Sione |
| FAMILY NAME | Crawford |
| SIGNATURE | CRAWFORD S |
| AFFILIATIONS | Harm Reduction Victoria Melbourne Australia |
| VERIFIED | No |
| TOTAL WORKS | 20 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 20 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2010 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Intranasal Mucosal Atomiser Devices: A Novel Harm Reduction Intervention
Factors Associated With Preferences for Opioid Agonist Therapies Among People Dependent on Opioids
Co-design of the Australian Prompt Response Network for a public-health focused intersectoral approach to information sharing on emerging drugs of concern
The rapid emergence of new psychoactive substances (NPS) and other emerging drugs of concern presents a significant global public health challenge, necessitating agile and interconnected drug information systems to identify and communicate risks. In Australia, responses have traditionally been localized, lacking a nationally coordinated system to rapidly share information about emerging drug threats. The National Center for Clinical Research on E…
Stigma by association among alcohol and other drug and harm reduction workers: Implications for workplace outcomes
Information acquisition and dissemination among a sample of people who inject drugs in Australia
Parents who inject drugs: Demographics, care arrangements and correlates for child placement in out‐of‐home care
Time for Australia to increase take away doses in opioid agonist treatment
Covid ‐19 vaccine attitudes and facilitators among people in Australia who inject drugs
People engaged in opioid agonist treatment as a counterpublic during the Covid ‐19 pandemic in Australia: A qualitative study
People who use drugs in hospital settings: ‘Moving towards a person‐centred harm reduction model’
People who use drugs often continue to use drugs while in hospital. However, health‐care systems often expect abstinence from drugs as a condition of engagement in various services. This commentary piece proposes that this approach is inconsistent with the principles of person‐centred care. A harm reduction‐based approach in conjunction with collaboration of people who use drugs is proposed as a model for providing person‐centred care to people w…
Evaluation of a person-centred, nurse-led model of care delivering hepatitis C testing and treatment in priority settings: A mixed-methods evaluation of the Tasmanian Eliminate Hepatitis C Australia O…
Providing outreach hepatitis C services in community-based services was effective in engaging people living with and at-risk of hepatitis C, in education, testing, and care. Nurse-led, person-centred care was critical to the success of the project. Our evaluation underscores the importance of employing a partnership approach when delivering hepatitis C models of care in community settings, and incorporating workforce education and capacity-buildi…
You'll come in and dose even in a global pandemic”: A qualitative study of adaptive opioid agonist treatment provision during the Covid-19 pandemic
Rigidity in the delivery of OAT has been an impediment to achieving health and wellbeing over past decades. To sustain health-promoting environments for people receiving OAT, the wider impacts of the complex system should be acknowledged beyond narrowly defined outcomes relating solely to the medication. Centring people receiving OAT in their own care plans will ensure adaptations in the complex system of OAT provision are responsive to the indiv…
I just thought that was the best thing for me to do at this point’: Exploring patient experiences with depot buprenorphine and their motivations to discontinue
Depot buprenorphine remains a promising treatment for OUD and offers potential to improve treatment adherence. Instances of restricted OAT choice and consumer concerns regarding a lack of agency must be addressed in order to enhance therapeutic relationships. Clinicians and other healthcare workers in this field also need greater access to information about depot buprenorphine to better address issues patients face during treatment. More research…
Covid ‐19 vaccine acceptability among people in Australia who inject drugs: Implications for vaccine rollout
Covid ‐19 vaccine acceptability among people in Australia who inject drugs: Update from the 2021 Illicit Drug Reporting System interviews
People who inject drugs may be at higher risk of COVID‐19 transmission and more severe negative health outcomes following COVID‐19 infection. Early research on hypothetical COVID‐19 vaccines suggests this population may be less likely to accept vaccination. This commentary extends this research by presenting vaccine intention data from Illicit Drug Reporting System interviews conducted in June–July 2021, in the early stages of vaccine rollout, wi…
Treading lightly: Finding the best way to use public health surveillance of hepatitis C diagnoses to increase access to cure
Characterising the policy influence of peer-based drug user organisations in the context of hepatitis C elimination
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy
Shouting through bullet-proof glass: Some reflections on pharmacotherapy provision in one Australian clinic
Working with the “hierarchy in the Underworld”: Insights for Communication Skills Training with Peer Educators
Peer education programs emphasize training in communication skills but provide little direction on training content. This research examines the specific strategies used by people who inject drugs (PWID) when engaging peers in education to promote safer injecting and to prevent the transmission of blood-borne viruses. People who inject drugs (PWID) participated in a series of three focus groups to develop peer education messages and strategies whi…
No prominent works on this page.
Working with the “hierarchy in the Underworld”: Insights for Communication Skills Training with Peer Educators
Peer education programs emphasize training in communication skills but provide little direction on training content. This research examines the specific strategies used by people who inject drugs (PWID) when engaging peers in education to promote safer injecting and to prevent the transmission of blood-borne viruses. People who inject drugs (PWID) participated in a series of three focus groups to develop peer education messages and strategies whi…
Shouting through bullet-proof glass: Some reflections on pharmacotherapy provision in one Australian clinic
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy
Characterising the policy influence of peer-based drug user organisations in the context of hepatitis C elimination
Treading lightly: Finding the best way to use public health surveillance of hepatitis C diagnoses to increase access to cure
Covid ‐19 vaccine acceptability among people in Australia who inject drugs: Implications for vaccine rollout
Covid ‐19 vaccine acceptability among people in Australia who inject drugs: Update from the 2021 Illicit Drug Reporting System interviews
People who inject drugs may be at higher risk of COVID‐19 transmission and more severe negative health outcomes following COVID‐19 infection. Early research on hypothetical COVID‐19 vaccines suggests this population may be less likely to accept vaccination. This commentary extends this research by presenting vaccine intention data from Illicit Drug Reporting System interviews conducted in June–July 2021, in the early stages of vaccine rollout, wi…
Covid ‐19 vaccine attitudes and facilitators among people in Australia who inject drugs
People engaged in opioid agonist treatment as a counterpublic during the Covid ‐19 pandemic in Australia: A qualitative study
People who use drugs in hospital settings: ‘Moving towards a person‐centred harm reduction model’
People who use drugs often continue to use drugs while in hospital. However, health‐care systems often expect abstinence from drugs as a condition of engagement in various services. This commentary piece proposes that this approach is inconsistent with the principles of person‐centred care. A harm reduction‐based approach in conjunction with collaboration of people who use drugs is proposed as a model for providing person‐centred care to people w…
Evaluation of a person-centred, nurse-led model of care delivering hepatitis C testing and treatment in priority settings: A mixed-methods evaluation of the Tasmanian Eliminate Hepatitis C Australia O…
Providing outreach hepatitis C services in community-based services was effective in engaging people living with and at-risk of hepatitis C, in education, testing, and care. Nurse-led, person-centred care was critical to the success of the project. Our evaluation underscores the importance of employing a partnership approach when delivering hepatitis C models of care in community settings, and incorporating workforce education and capacity-buildi…
You'll come in and dose even in a global pandemic”: A qualitative study of adaptive opioid agonist treatment provision during the Covid-19 pandemic
Rigidity in the delivery of OAT has been an impediment to achieving health and wellbeing over past decades. To sustain health-promoting environments for people receiving OAT, the wider impacts of the complex system should be acknowledged beyond narrowly defined outcomes relating solely to the medication. Centring people receiving OAT in their own care plans will ensure adaptations in the complex system of OAT provision are responsive to the indiv…
I just thought that was the best thing for me to do at this point’: Exploring patient experiences with depot buprenorphine and their motivations to discontinue
Depot buprenorphine remains a promising treatment for OUD and offers potential to improve treatment adherence. Instances of restricted OAT choice and consumer concerns regarding a lack of agency must be addressed in order to enhance therapeutic relationships. Clinicians and other healthcare workers in this field also need greater access to information about depot buprenorphine to better address issues patients face during treatment. More research…
Stigma by association among alcohol and other drug and harm reduction workers: Implications for workplace outcomes
Information acquisition and dissemination among a sample of people who inject drugs in Australia
Parents who inject drugs: Demographics, care arrangements and correlates for child placement in out‐of‐home care
Time for Australia to increase take away doses in opioid agonist treatment
Co-design of the Australian Prompt Response Network for a public-health focused intersectoral approach to information sharing on emerging drugs of concern
The rapid emergence of new psychoactive substances (NPS) and other emerging drugs of concern presents a significant global public health challenge, necessitating agile and interconnected drug information systems to identify and communicate risks. In Australia, responses have traditionally been localized, lacking a nationally coordinated system to rapidly share information about emerging drug threats. The National Center for Clinical Research on E…
Intranasal Mucosal Atomiser Devices: A Novel Harm Reduction Intervention
Factors Associated With Preferences for Opioid Agonist Therapies Among People Dependent on Opioids
Medicine (17 works) · HIV, Drug Use, Sexual Risk (13 works) · Opioid Use Disorder Treatment (12 works) · Nursing (10 works) · Political science (10 works) · Psychiatry (9 works) · Public health (9 works) · Family medicine (8 works) · Psychology (8 works) · Substance Abuse Treatment and Outcomes (8 works)